Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
2.700
+0.010 (0.37%)
At close: Apr 28, 2026, 4:00 PM EDT
2.750
+0.050 (1.85%)
After-hours: Apr 28, 2026, 7:55 PM EDT
Ovid Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Ovid Therapeutics stock have an average target of 4.60, with a low estimate of 3.00 and a high estimate of 7.00. The average target predicts an increase of 70.37% from the current stock price of 2.70.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ovid Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $7 | Buy | Reiterates | $7 | +159.26% | Apr 15, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $2 → $4 | Strong Buy | Maintains | $2 → $4 | +48.15% | Apr 9, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +48.15% | Mar 26, 2026 |
| Wedbush | Wedbush | Buy Maintains $5 → $7 | Buy | Maintains | $5 → $7 | +159.26% | Mar 20, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2 | Strong Buy | Reiterates | $2 | -25.93% | Dec 22, 2025 |
Financial Forecast
Revenue This Year
230.78K
from 7.25M
Decreased by -96.82%
Revenue Next Year
275.40K
from 230.78K
Increased by 19.34%
EPS This Year
-0.53
from -0.23
EPS Next Year
-0.64
from -0.53
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.2M | 1.2M | ||||||
| Avg | 230,775 | 275,400 | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -83.9% | 405.3% | ||||||
| Avg | -96.8% | 19.3% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.36 | -0.40 | |||
| Avg | -0.53 | -0.64 | |||
| Low | -1.02 | -1.27 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.